Publication
Abstract
Realization of part of clinical trial called: A prospective, randomized, open, two-arm clinical phase III trial evaluating the frequency of remission without treatment (TFR) in patients with Philadelphia chromosome-positive CML after consolidation therapy with nilotinib 300 mg BID with two different durations